Unassociated Document Company Contact: Investor Relations Contact: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer (brian.ritchie@fd.com) (jbrooks@senesco.com) (212) 850-5683 (732) 296-840

AMEX ACCEPTS SENESCO TECHNOLOGIES' PLAN OF COMPLIANCE

NEW BRUNSWICK, N.J. (January 19, 2010) -Senesco

Technologies, Inc. (the "Company" or "Senesco") (NYSE Amex: SNT) announced today that on

January 14, 2010, it received notice from the NYSE Amex LLC

("NYSE") stating that the exchange had accepted the Company's compliance plan

and granted it an extension until April 29, 2011 to regain compliance with the

NYSE's continued listing standards. As previously disclosed, Senesco

is not in compliance with Section 1003(a)(iii) of the NYSE company guide with

stockholder's equity of less than $6,000,000 and losses from continuing

operations and/or net losses in its five most recent fiscal

years. Based on this, the Company submitted a plan advising the NYSE

of action it will take, that the Company believes would bring Senesco into

compliance with the NYSE's continued listing standards by the end of the

the extension period, the Company remains subject to periodic review by NYSE

Staff. Failure to make progress consistent with the plan or to regain

compliance with the continued listing standards by the end of the extension

period could result in Senesco being delisted from the NYSE.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or

delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain inflammatory and ischemic diseases. Senesco takes

its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

Certain statements included in this

press release are forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Actual results could differ

materially from such statements expressed or implied herein as a result of a

variety of factors, including, but not limited to: the ability of the Company to

consummate additional financings; the development of the Company's gene

technology; the approval of the Company's patent applications; the successful

implementation of the Company's research and development programs and joint

ventures; the success of

the Company's license agreements; the acceptance by the market of the

Company's products; success of the Company's preliminary studies and preclinical

research; competition and the timing of projects and trends in future operating

performance, the Company's ability to comply with the continued listing

standards of the AMEX, as well as other factors expressed from time to time in

the Company's periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press

release should be read in conjunction with the Company's periodic filings with

the SEC. The forward-looking statements contained herein are made

only as of the date of this press release, and the Company undertakes no

obligation to publicly update such forward-looking statements to reflect

subsequent events or circumstances.